10q10k10q10k.net
IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.IDYAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.

Q3 2025Q3 2024Q2 2024Q1 2024Q3 2022

Revenue

$0

Gross Profit

N/A

Operating Profit

$-66.9M

Net Profit

$-51.8M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.60

IDEAYA Biosciences, Inc. Q3 FY2024 Financial Summary

IDEAYA Biosciences, Inc. reported revenue of $0 for Q3 FY2024, with a net profit of $-51.8M (down 88.9% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-51.8M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 FY2024

IDEAYA Biosciences, Inc. Quarterly Revenue & Net Profit History

IDEAYA Biosciences, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$207.8M—$119.2M57.4%
Q3 FY2024$0—$-51.8MN/A
Q2 FY2024$0—$-52.8MN/A
Q1 FY2024$0—$-39.6MN/A
Q3 FY2022$29.7M+230.9%$1.6M5.4%

Income Statement

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Revenue$29.7M$0$0$0$207.8M
YoY Growth230.9%N/AN/AN/AN/A

Balance Sheet

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Assets$410.9M$961.5M$973.7M$1.24B$1.19B
Liabilities$42.1M$26.2M$42.0M$59.5M$93.1M
Equity$368.8M$935.3M$931.7M$1.18B$1.09B

Cash Flow

Q3 2022Q1 2024Q2 2024Q3 2024Q3 2025
Operating CF$-24.2M$-43.8M$-32.9M$-49.2M$142.2M